Tiziana Life Sciences Ltd. Common Shares TLSA
Analyst Ratings
- Consensus
- Buy — 1 Buy · 0 Hold · 0 Sell (1 analysts)
- Avg. Price Target
- $7.00 (+554.2% upside)
Key Stats
- Today's Range
- $1.07 – $1.14
- 50-Day Range
- $0.76 – $1.25
- 52-Week Range
- $0.76 – $2.35
- Volume
- 275K shs
- Average Volume
- 623K shs
- Market Cap
- $136.17 million
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 0.00%
- Days to Cover
- 1.00
About Tiziana Life Sciences Ltd. Common Shares
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.
Related Stocks
Compare head-to-head: TLSA vs NVDA·TLSA vs AAPL·TLSA vs GOOGL·TLSA vs GOOG
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.